|Avg Daily Vol (13 Wks)||160,571.36|
- Last trade 9/23/2014 4:00 PM ET
|Net Profit Margin||-92.19%|
|Market Cap||58.55 Mil|
|Shares Outstanding||21.14 Mil|
- * last 12 months
- TheStreet.com | 9/18/2014
- OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-RPR Newswire | 9/16/2014
- TheStreet.com | 8/27/2014
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.